Particle Sciences Inc. and DelAQUA Pharmaceuticals Announce Strategic Collaboration

Particle Sciences Inc. and DelAQUA Pharmaceuticals Announce Strategic Collaboration to Advance Implantable and Sustained-Release Drug Delivery Solutions

BETHLEHEM, PA – January 29, 2026 – Particle Sciences Inc. (PSI), a division of global CDMO Agno Pharma, today announced a strategic collaboration with DelAQUA Pharmaceuticals, Inc. to integrate DelAQUA’s innovative polymeric micelle drug delivery platform into PSI’s comprehensive development offerings. The partnership combines PSI’s decades of expertise in implantable and sustained-release formulation development with DelAQUA’s breakthrough solubility-enhancing technology to deliver next-generation drug delivery solutions to pharmaceutical and biotech customers worldwide.

The collaboration addresses a critical industry need for advanced formulation technologies that can improve the bioavailability of poorly soluble compounds while extending therapeutic delivery timelines. By integrating DelAQUA’s highly customizable and adaptive platform with PSI’s specialized capabilities in nanoformulation, hot melt extrusion, and analytical chemistry, the partnership will enable accelerated development timelines and formulations precisely aligned with customers’ target product profiles.

Particle Sciences Inc. (PSI) is excited to collaborate with DelAQUA, harnessing its transformative drug development platform to expand and enhance our development offerings to our global customer base. As a CDMO with decades of experience in implantable and sustained-release formulation development, we recognize the opportunity to bridge technology gaps using DelAQUA’s highly customizable and adaptive platform. This collaboration will allow us to accelerate our customers’ development timelines and deliver formulations aligned with their target product profiles. This marks an important step in redefining what’s possible in drug delivery innovation. – Jite Okoh,  Director, Device and Implant Development, Particle Sciences

DelAQUA’s polymeric micelle platform represents a significant advancement in addressing the challenges of poorly soluble and unstable drug compounds. The technology utilizes novel polymers at low concentrations to effectively improve the solubility of active pharmaceutical ingredients (APIs), widening the therapeutic index while reducing the volume and complexity of formulations. This approach has shown promise in enhancing therapeutic efficacy while minimizing adverse side effects associated with high excipient loads in conventional delivery systems.

As DelAQUA sets its sights on drug delivery applications beyond oral and injectable products, we immediately identified the Particle Sciences team at Agno as the ideal development partner. They not only bring sparkling technical capabilities in nanoformulation, hot melt extrusion and analytical chemistry to the table, they have the agility and creativity necessary for successful outcomes for our novel implantable and sustained release formulations. We look forward to working with PSI on our own projects while providing another drug formulation technology to offer to their customers. – Bruce L. Frank, PhD, President and Chief Scientific Officer, DelAQUA Pharmaceuticals

About Particle Sciences Inc.

Particle Sciences Inc. (PSI), a division of Agno Pharma, is a leading contract development and manufacturing organization specializing in pre-clinical and clinical stage drug product formulation. Founded in 1991 and based in Bethlehem, Pennsylvania, PSI offers comprehensive development services including formulation development, analytical and bioanalytical testing, physical characterization, and clinical manufacturing. The company has deep expertise in developing solutions for poorly soluble and highly potent compounds in both sterile and non-sterile environments, with specialized capabilities in nanoformulation, hot melt extrusion, implantable devices, and sustained-release formulations. Following its acquisition by Agno Pharma in December 2023, PSI continues to provide client-centric solutions while benefiting from the resources and stability of a global pharmaceutical organization.

About DelAQUA Pharmaceuticals, Inc.

DelAQUA Pharmaceuticals is a specialty pharmaceutical company headquartered in Chapel Hill, North Carolina, that has developed a breakthrough drug formulation platform utilizing advanced polymeric micelle technology. DelAQUA’s proprietary platform improves the solubility and stability of active pharmaceutical ingredients (APIs) by using novel polymers at low concentrations, effectively widening the therapeutic index of APIs while reducing formulation complexity. As demonstrated by DelAQUA’s collaborations with several multinational pharmaceutical companies, smaller pharmaceutical firms, and major research universities, the company’s technology has applications across multiple therapeutic areas. With the broad number of precise design properties available with this technology, novel drug formulations with improved therapeutic outcomes and additional intellectual property protection are on the horizon. The company is led by Bruce L. Frank, PhD, President and Chief Scientific Officer, a recognized expert in pharmaceutical drug product development and formulation science.